A Survey on the Adjuvant Role of Naloxone Alone or Combined with Alum in Vaccination Against Fasciolosis in BALB/c Mice. by Azizi, H et al.
See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/331232868
A Survey on the Adjuvant Role of Naloxone Alone or Combined with Alum in
Vaccination Against Fasciolosis in BALB/c Mice
Article  in  Acta Parasitologica · February 2019
DOI: 10.2478/s11686-019-00030-2
CITATIONS
0
READS
49
9 authors, including:
Some of the authors of this publication are also working on these related projects:
The Association between Prolonged Jaundice and UGT1A1 Gene Polymorphism (G71R) in Gilbert's Syndrome View project
I working on Nanomedicine Application of Nanoparticle. Our Focus is Evaluation Animicrobal Effitiency of Nanoparticle against large number of spieces. We want to try
find out biosynthesis mechanism of Nanoparticles. View project
Hakim Azizi
Zabol University Of Medical Sciences
17 PUBLICATIONS   82 CITATIONS   
SEE PROFILE
Ali Bazi
Zabol University Of Medical Sciences
43 PUBLICATIONS   53 CITATIONS   
SEE PROFILE
Ali Khamesipour
Tehran University of Medical Sciences
168 PUBLICATIONS   2,890 CITATIONS   
SEE PROFILE
Hajar Yaghoobi
Shahid Beheshti University of Medical Sciences
11 PUBLICATIONS   68 CITATIONS   
SEE PROFILE
All content following this page was uploaded by Aliyar Mirzapour on 03 March 2019.
The user has requested enhancement of the downloaded file.
Vol.:(0123456789) 
Acta Parasitologica 
https://doi.org/10.2478/s11686-019-00030-2
ORIGINAL PAPER
A Survey on the Adjuvant Role of Naloxone Alone or Combined 
with Alum in Vaccination Against Fasciolosis in BALB/c Mice
Hakim Azizi1 · Hadi Mirzaeei2 · Amin Bagheri3 · Ali Bazi4 · Ali Khamesipour5 · Hajar Yaghoobi6 · Aliyar Mirzapour7 · 
Mehrdad Khatami8 · Samira Elikaee9
Received: 13 September 2018 / Accepted: 20 December 2018 
© Witold Stefański Institute of Parasitology, Polish Academy of Sciences 2019
Abstract
Background Fasciolosis is a zoonotic parasitic disease imposing a heavy load of livestock losses worldwide.
Purpose We aimed to evaluate immune-stimulatory effects of naloxone (NLX), an opioid receptor antagonist, in combina-
tion with alum in mice vaccinated with excretory–secretory antigens (E/S) of Fasciola hepatica.
Methods 8-week-old female BALB/c mice were subcutaneously vaccinated using E/S antigens of F. hepatica. Experimental 
groups (14 mice per group) included: vaccine (E/S antigen), alum vaccine (E/S antigen plus alum), NLX vaccine (E/S antigen 
plus NLX), and alum–NLX vaccine (E/S antigen plus a mixture of alum–NLX). The control group was infused with PBS. 
Lymphocyte proliferation and the levels of IFN-γ, IL-4, IgG2a, IgG1, and total IgG were measured.
Results Mice vaccinated with NLX or alum–NLX adjuvants showed significantly higher rates of lymphocyte proliferation, 
IFN-γ, total IgG, and IgG2a levels. The mice that were injected with alum showed a significantly higher concentration of 
IL-4. Ratios of IFN-γ/Il-4 and IgG2a/IgG1 were significantly higher in the NLX and alum–NLX groups in comparison with 
the groups vaccinated either with alum or without any adjuvant. A significantly higher protection rate (62.5%) was seen in 
mice vaccinated with the alum–NLX adjuvant compared to the other groups.
Conclusion NLX can be effective in conferring cellular immunity and protection against F. hepatica. It is recommended to 
consider this agent as a potential adjuvant in vaccines against fasciolosis.
Keywords Fasciolosis · Adjuvant · Aluminum sulfate · Naloxone · Vaccine
Introduction
Fasciolosis is a zoonotic parasitic disease caused by hepatic 
trematodes; Fasciola hepatica and Fasciola gigantica. The 
disease imposes a heavy load of livestock losses worldwide 
with a high financial burden mainly on the food industries 
[6, 34]. Chemotherapy, as the only available treatment strat-
egy against fasciolosis, is accompanied by both safety and 
drug resistance concerns [17, 29]. Therefore, it is essential 
to develop an effective vaccine against fasciolosis.
The success of helminthic parasites in hosts may be 
related to their capability in suppressing the cell-mediated 
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immune responses [33]. In fact, the interaction of Fas-
ciola species with immune cells such as dendritic cells 
(DCs) and macrophages could promote a non-destructive 
CD4 + Th2 response [10], and subsequently a boost in 
anti-inflammatory regulatory cytokines such as IL-4, 
IL-5, and IL-13. This is also characterized by an antibody 
response predominated with IgG1 (in mouse), IgE and IgA 
isotypes. On the other hand, Th1 lymphocytes known as 
IFN-γ secreting cells are kept suppressed during immune 
responses against these parasites [1, 38].
The global increase in life expectancy in the current 
century is partly due to the management of infectious dis-
ease by implementation of efficient vaccines. This surely 
has been one of the most successful and groundbreaking 
achievements in medical sciences. In accordance, vaccina-
tion appeared to be a potential way to fight against drug-
resistant fasciolosis [20, 34]. Adjuvants are vaccine-con-
jugated factors promoting the immune-inductive capacities 
of vaccines. Adjuvants can enhance both the intensity and 
direction of immune responses [3, 46]. A pathogenic agent 
may be eradicated by the activity of both humoral and 
cellular immunities. However, the cellular immunity and 
Th1 response are capable of effectively eliminating the 
intracellular pathogens.
Alum is currently the only adjuvant which is approved 
by FDA [11], while only a few additional adjuvants have 
been licensed by other facilities such as the European 
Medicines Agency [26, 28]. Alum is effective in the 
induction of humoral immunity. However, when there is a 
need for efficient induction of cellular immunity and Th1 
response, alum is not a competent adjuvant [11, 27]. One 
of the drawbacks in the process of commercializing the 
vaccine adjuvants is the safety issue. For example, Fre-
und’s adjuvant is an agent that can promote the cellular 
side of the immunity, but it is not appropriate for use in 
humans due to the intolerability of the adjuvant in human 
beings [9].
Opioid are immune-modulating factors attenuating 
immune-inductive effects of vaccines [19]. Naloxone 
(NLX) is an FDA-approved opioid receptor antagonist 
administrated for individuals with respiratory toxicity 
induced by opioid peptides [5, 21, 47]. NLX has been 
reported to boost the vaccine-induced immune responses 
in vaccination experiments for a number of human infec-
tions [22, 26–28, 42, 47]. NLX’s capability in induction 
of Th1 response and cell-mediated cytotoxicity potentiates 
the agent as a suitable adjuvant for vaccination against 
Fasciola species [21, 35]. Based on various developmental 
stages, excretory–secretory (E/S) antigens of F. hepatica 
contain key molecules leading to pathogenicity [24]. An 
effective vaccine against hepatic flukes such as Fasciola 
should be able to reduce fluke burden in liver. As E/S anti-
gen of F. hepatica constitutes key pathogenesis molecules, 
E/S antigen-based vaccines can be potential targets for 
developing effective vaccines against this disease [24]. In 
the present study, the effects of NLX have been evaluated 
as an individual or alum-associated adjuvant in stimulation 
of cellular and Th1 immune responses in mice vaccinated 
against F. hepatica using E/S antigen vaccine. Further-
more, the protection rate was also assessed in immunized 
mice infected with F. hepatica.
Materials and Methods
Mice
Seventy female BALB/c mice with age of 6–8 weeks were 
purchased from Razi Vaccine and Serum Research Insti-
tute, Hesark, Iran. The animals were maintained under 
standard specific pathogen-free conditions. All experi-
ments were performed according to the Animal Care and 
Use Protocol of Zabol University of Medical Sciences. 
The study was approved by Ethical Committee of Zabol 
University of Medical Sciences.
Preparation of Metacercariae
Metacercariae for vaccination experiment were prepared 
by infecting the laboratory-cultured snail host, Lymnaea 
truncatula, with miracidia derived from F. hepatica eggs. 
The eggs were obtained from bile ducts and gall bladders 
of naturally infected sheep slaughtered in a local abat-
toir. The eggs were further incubated in 0.85% dechlorated 
water in a dark place for 2 weeks. After the incubation 
period, the eggs were stimulated with light for 2 h for 
hatching of miracidia. At 45 days post-infection, cercariae 
were shed from the snails, then settled on the floating cel-
lophane papers, and immediately transformed into meta-
cercariae. The metacercariae were collected and kept at 
4 °C until use.
Preparation of Excretory and Secretory (E/S) 
Antigens
To prepare excretory–secretory antigens (E/S), adult F. 
hepatica were collected from bile ducts and gall bladders 
of naturally infected sheep, and washed six times with 
0.85% dechlorated water to remove any trace of bile, 
blood, or contamination. The flukes were then moved into 
RPMI1640 cell culture medium (1 fluke per 5 ml), sup-
plemented with 100 IU penicillin, and 100 µg/ml strepto-
mycin and incubated at 37 °C. The culture medium was 
collected and centrifuged at 15,000g at 37 °C for 30 min 
every 6 h for 24 h [31]. The supernatant containing E/S 
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antigens was collected, and the protein concentration was 
determined using Lowry’s method (Bio-Rad). All samples 
were kept at − 80 °C until use (Fig. 1).
Immunization Protocol
The alum–NLX mixture was prepared by thoroughly mix-
ing 50 µl of PBS containing 6 mg/ml of NLX (Sigma, 
Germany) with 50 µl of alum (aluminum phosphate gel, 
Sigma, Germany). The mixture was incubated at 4 °C in a 
sterile condition for 72 h [11, 27, 41].
Five groups of mice (14 per group), as described in 
Table  1, were subcutaneously vaccinated. The animals 
received booster injections at days 14 and 28.
Lymphocyte Proliferation Assay
Two weeks after the last immunization, five mice of each 
group were slaughtered, and spleens were recovered. Sple-
nocyte suspensions were prepared by squishing the spleens 
through a wire mesh under sterile conditions. The red 
blood cells were eliminated using ammonium chloride, 
and splenocytes were suspended in RPMI 1640 medium 
supplemented with 10% fetal calf serum (FCS) (Gibco-
BRL), 2 mM l-glutamine, and 25 mM HEPES. Diluted cell 
Fig. 1  The timeline of the study. After culturing adult F. hepatica 
parasites, excretory/secretory antigens were recovered each 24  h. 
After obtaining the intended concentrations, the antigens were incor-
porated with adjuvants and then injected into mice at three occasions 
(days 0, 14, and 28). Two weeks after the last injection, the mice in 
each group were divided into two groups. The mice in one group 
were used for cytokine assay, and the remaining were subjected to 
protection assay
Table 1  Experimental groups designed for vaccination against F. 
hepatica 
a 100 µl of E/S antigens and PBS suspension was absorbed in alum
b 100 µl of E/S antigens and PBS suspension was absorbed in nalox-
one
c 50  µl of the E/S antigens suspension was absorbed in 100  µl of 
alum–naloxone mixture
Experimental groups Vaccination constituents
PBS
(volume, µl)
E/S antigens
(20 µg/ml)
(volume, µl)
Adjuvant
(volume, µl)
Alum Naloxone
Control 150 – – –
Vaccine 100 50 – –
Alum  vaccinea 50 50 50 –
Naloxone  vaccineb 50 50 – 50
Alum–naloxone 
 vaccinec
– 50 50 50
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suspensions (100 μl) were then seeded in 96-well flat-bottom 
culture plates at a density of 1 × 106 cells/ml per well. The 
cells were then stimulated with 10 μl of the E/S antigens 
(10 µg/ml). Concanavalin A (Con A, 5 μg/ml, Sigma) and 
culture medium served as positive and negative controls, 
respectively.
After 72 h, cell proliferation was measured using the 
MTT (3[4,5-dimethylthiazol-2-ml]-2,5-diphenyltetrazolium 
bromide; thiazolyl-blue, Sigma, Germany) assay. Briefly, 
20 μl of MTT solution was added to each well, and the 
plate was incubated at 37 °C for 4 h. The supernatant was 
discarded from each well, and formazan crystals were solu-
bilized by adding 100 µl of dimethyl sulfoxide (DMSO). 
After 20 min, the optical density (OD) of each well was 
read at 540 nm. The stimulation index (SI) was calculated 
as follows:
Cytokines Assay
Two weeks after the last immunization, splenocytes were 
harvested and cultured for 72 h. The supernatants of the 
culture mediums were collected, and the levels of IFN-γ 
and IL-4 were measured using commercial enzyme-linked 
immunosorbent assay (ELISA kit, eBscience, USA) accord-
ing to the manufacturer’s instructions. All assays were per-
formed in triplicate.
Determination of IgG and Isotype Level
Levels of IgG, IgG1 and IgG2a were measured at 2 weeks 
after the last immunization. Total IgG, IgG1 and IgG2a 
levels were determined in the sera of five mice from each 
group [14]. Briefly, following overnight coating of micro-
titer plates with 100 µl of the E/S antigen (at 4 °C, with a 
concentration of 5 µg/ml in 0.05 M bicarbonate buffer, pH 
9.6), the plates were washed two times with PBS contain-
ing 0.05% Tween 20 (PBST-20), pH 7.4. After that, non-
specific binding sites were blocked with PBS containing 
5% FCS for 2 h at 37 °C. After washing the plates with 
PBST, sera were diluted in 1% PBST-20 (1:100), and were 
transferred to each well. Plates were incubated for 2 h at 
room temperature, washed three times and incubated with 
HRP-conjugated rabbit anti-mouse for total IgG, IgG2a or 
IgG1. After sufficient washes, the reaction was developed 
by adding 200 ml of TMB/H2O2 substrate. The reaction 
was terminated by adding 50 µl of 2 N H2SO4. The ODs 
were read at 450 nm in a microplate reader (Thermo Sci-
entific Multiskan FC, USA). All assays were performed in 
triplicate.
Stimulation index
=
Mean OD of stimulated cells −Mean OD of the Blank
Mean OD of unstimulated cells
Evaluation of Fluke Burden in Biliary–Hepatic 
System
To evaluate the rate of protection against F. hepatica, the 
flukes were counted in the biliary–hepatic tissues of the 
immunized mice after challenge with the 6-week-old meta-
cercariae. Two weeks after the last immunization, the mice 
were orally infected with 30 metacercariae. Six weeks later, 
the mice were sacrificed, and their peritoneal cavities were 
opened, and the parasites were collected from the livers. The 
parasites obtained from the livers were counted and used to 
calculate the percentage of protection according to the fol-
lowing formula [8]:
 where “A” represents the mean of worms recovered from the 
non-immunized (control group) and “B” represents the mean 
of worms recovered from the immunized group.
Statistical Analyses
SPSS Ver. 21 (Chicago, IL, USA) was used to analyze the 
data. The MTT assay, cytokine levels, and the parasitic 
loads in livers were analyzed by one-way analysis of vari-
ance (ANOVA) and independent samples student’s t test. 
A P value of less than 0.05 was considered as statistically 
significant.
Results
Lymphocyte Proliferation
Lymphocyte proliferation (represented as SI) was signifi-
cantly higher in the group of mice immunized with the E/S 
vaccine in combination with alum–NLX mixture compared 
to lymphocyte proliferation of mice in the other groups 
Protection (%) = (A − B) ∕A × 100
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Fig. 2  Differences between SI concentrations in the studied vacci-
nated groups CONT control, VAC vaccine, AL alum, NLX naloxone
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(P < 0.001). Furthermore, a significantly higher SI was 
observed for lymphocytes derived from the mice immu-
nized with NLX compared to the mice that received alum 
(P = 0.02), E/S vaccine (P = 0.001) or PBS alone (P < 0.001, 
Fig. 2).
Cytokine Pattern
The results of ELISA test have been presented in Fig. 3. 
The mice immunized with alum–NLX mixture showed a 
significantly (P < 0.001) higher IFN-γ level than the mice 
that received NLX, alum, E/S antigens alone, or the PBS 
alone (Fig. 3a).
The group of mice that received E/S antigens in combi-
nation with alum showed a significantly (P = 0.001) higher 
IL-4 level than the groups of mice treated with the E/S anti-
gens plus either NLX, or alum–NLX (Fig. 3b).
As shown in Fig. 2c, IFN-γ/IL-4 ratio was significantly 
(P < 0.001) higher in the mice immunized with E/S antigens 
in combination with alum–NLX mixture than the ratio in the 
mice that received E/S antigens with either NLX, or alum.
Antibody Levels
As shown in Fig. 4a, a significantly (P < 0.001) higher level 
of anti-F. hepatica IgG2a was found in the group of animals 
infused with E/S antigens combined with the alum–NLX 
mixture compared with the group that received E/S antigens 
mixed with alum. However, the difference was not statisti-
cally significant compared with the group administrated E/S 
antigens plus NLX.
The IgG1 level was significantly (P < 0.001) higher in the 
mice administrated E/S antigens and either alum–NLX mix-
ture or alum compared with the groups of mice that received 
E/S vaccine either with NLX or PBS (Fig. 4b).
The total IgG level showed significantly higher levels in 
the mice vaccinated with alum–NLX mixture compared to 
the groups vaccinated with either NLX, or alum (P = 0.01) 
(Fig. 4c).
As shown in Fig. 4d, IgG2a/IgG1 ratio was significantly 
(P < 0.001) higher in the group transfused with NLX com-
pared to the groups that received either the alum–NLX mix-
ture, or alum.
Worm Recovery
Four mice were alive at the end of week 6 in the alum–NLX 
vaccine group. Fluke enumeration was conducted immedi-
ately after the death of mice. The death was preceded by 
the mice becoming weak, and fatigued, except for the mice 
that survived until the end which seemed happier. The liver 
pathological changes in the unimmunized group included 
discoloring of liver to a grayish-white hue, more thickness 
of bile ducts, and surface scars on livers at the time of fluke 
recovery. Nevertheless, microscopical liver pathological 
changes and liver enzymes were not documented.
The highest protection rate (62.5%) was recorded in the 
mice infused with alum–NLX as the adjuvant (Table 2). The 
rate of worm recovery was expressed as mean ± SEM. The 
group of mice immunized with E/S antigens accompanied by 
alum–NLX adjuvant showed an average number of parasites 
as 2.4 ± 0.7 per mouse which was significantly (P < 0.001) 
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Fig. 3  Concentrations of IFN-γ and IL-4 cytokines in different vacci-
nated groups; a INF-γ, b IL-4, and c IFN- γ/IL-4 ratio concentration 
of INF-γ was the highest in animals that their vaccination was accom-
panied by alum–NLX adjuvant, while the group that was infused with 
alum adjuvant showed higher IL-4 concentration. CONT control, VAC 
vaccine, AL alum, NLX naloxone
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lower than the number of worms recovered from animals 
that received E/S antigens along with either NLX or alum 
(Fig. 5).
Discussion
Adjuvant is an inevitable part of an effective vaccine. In 
the present study, the adjuvancity of NLX was assessed 
in mice vaccinated with E/S antigens of F. hepatica. This 
was the first report on the role of NLX as an adjuvant 
in a vaccination attempt against fasciolosis. We observed 
significantly higher lymphocytic proliferation, higher 
IFN-γ production, and higher IFN-γ/IL-4 ratio in the mice 
injected with alum–NLX compared to the mice that were 
vaccinated with alum or without any adjuvant. In addition, 
higher contents of IgG2a with increased ratio of IgG2a/
IgG1 were found in the mice administrated alum–NLX, 
and NLX adjuvants compared to the mice that received 
either alum or the vaccine alone. These observations were 
in accordance with a higher protection rate (62.5%) in the 
alum–NLX group.
Following Fasciola sp. infection, IFN-γ is temporary 
elevated in the acute phase of infection, however, the lev-
els of IFN-γ decline in chronic fasciolosis [16]. On the 
other hand, IL-4 is elevated during the acute phase, and 
remains at high levels during the chronic phase of the dis-
ease [17]. This pattern is known as alternative activation 
of immune system characterized by higher production of 
immunomodulatory cytokines such as IL-10, IL-4, IL-5, 
and TGF-β [7, 18]. Interaction of parasite-derived mol-
ecules with receptors of immune cells is thought to trig-
ger the immunomodulation process [12, 13, 15, 17, 38]. 
Researches have been dedicated to avoid non-protective 
Th2 immune response using opioid receptor antagonists 
[4, 28, 41].
NLX and naltrexone (NLT), another opioid antago-
nist, have been used in multiple studies as Th1 immune 
response-promoting adjuvants [4, 30, 36]. Khorshidvand 
et al. [30] assessed the efficacy of alum–NLX adjuvant 
in augmenting cellular immunity in the context of Toxo-
plasma gondii vaccination, and showed a significantly 
higher proliferative rate of lymphocytes in mice vacci-
nated with alum–NLX combination which is similar to 
our results. In addition, vaccine administration with either 
NLX or a combination of alum–NLX conferred higher 
production of IFN-γ indicating activation of Th1 response 
in the recent study [30]. In line with this, the alum–NLX 
adjuvant applied in vaccination against Salmonella typh-
imurium was associated with expansion of cytotoxic 
lymphocytes and Th1 response [27, 28]. The alum–NLX 
mixture showed similar immune-inductive properties as 
observed in our study (e.g., Th1 response, lymphocytic 
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CONT control, VAC vaccine, AL alum, NLX naloxone
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proliferation and increased IgG immunoglobulin response) 
when used in vaccinations against HIV [42], human papil-
lomaviruses [47], herpes simplex virus [22], and simplex 
virus type 1 [21]. Using the combined alum–NLX adjuvant 
resulted in significantly decreased ratio of cells infected 
with Brucella that was accompanied by higher produc-
tion of IFN-γ, IL-4, and IgG [36]. NLX was also effective 
in exploiting a cell-mediated immunity characterized by 
lymphocytic proliferation and Th1 response against Lis-
teria monocytogenes [26]. Similar to our observations, 
the combination of alum and NLT adjuvant boosted the 
efficiency of vaccines against Fasciola hepatica [4], Sal-
monella typhimurium [28], and Plasmodium berghei [41] 
by induction of lymphocytic proliferation, Th1 response, 
and production of organism-specific antibodies of IgG2a 
and IgG1 isotypes with dominance of IgG2a component.
NLX seemed to avoid such immunomodulatory inter-
actions, and can effectively accelerate cell-mediated 
immunity. In fact, opioid peptides can generate their 
immunomodulatory effects through both direct interactions 
with immune cells, and also through hormonal signaling 
pathways [37]. These peptides are known to interfere with 
vaccine function against pathogens. NLX may promote its 
stimulatory effects on immune responses through attenuat-
ing opioid-originated effects. In addition, NLX can boost 
the cellular-based immunity by promoting an inflamma-
tory state, and therefore activating cellular components of 
innate and acquired immunity [2]. In line with this, NLX 
promoted cell-mediated immunity through induction of 
neuropeptide inflammatory molecules. Furthermore, NLX 
can be associated with depression of regulatory T lympho-
cytes (CD4 +/CD25 +/FoxP3 +), and this reduction can be 
accompanied by a simultaneous increase in the number of 
cytotoxic lymphocytes and higher IFN-γ production [35]. 
Regulatory T lymphocytes can repress antigen-presenting 
cells such as dendritic cells (DCs), and further extinguish 
the cell-mediated immunity. Likewise, alum–NLX adjuvant 
has also been associated with cytokine profile corresponding 
to Th17 response which is known as another immunomodu-
latory process [47]. Although alum and NLX activate dif-
ferent immune responses (Th2 and Th1, respectively), the 
combined utilization of alum–NLX adjuvant significantly 
enhanced the Th1 response, which may indicate a synergistic 
effect for alum in augmentation of NLX-induced responses. 
This potential synergistic effect may further become of clini-
cal importance regarding the significantly lower protection 
rate of mice vaccinated with NLX in comparison to the mice 
administrated with alum–NLX.
In addition to the nature of adjuvant component, types 
of the antigenic parts of vaccines may also influence the 
outcomes of vaccination against pathogens [40]. E/S anti-
gen of F. hepatica contains different pathogenic molecules 
at different developmental stages with cathepsin L5, cath-
epsin L1g and cathepsin B being the prominent antigenic 
markers in adult, metacercariae, and young F. hepatica 
[24]. In the study of Jayaraj et al. [24], recombinant DNA 
vaccines of cathepsins B + L5 incorporated with Quil A 
adjuvant, an emulsion of water and non-mineral oil (Mon-
tanide) adjuvant, retrieved the lowest fluke recovery and 
liver damage index, as well as the highest protection rate 
compared to mice vaccinated with either single or other 
combinations of cathepsins B, L5 or L1g (representing 
Table 2  Protection rates 
rendered by different 
vaccination approaches against 
F. hepatica 
Groups Number of parasites per 
mouse
Number of parasites 
(mean ± SD)
Protection (%)
Control 5, 8, 6, 5, 6, 7, 8 6.4 ± 1.2 –
Vaccine 7, 6, 7, 7, 5, 5, 6 6.1 ± 0.8 4.6
Alum vaccine 4, 4, 4, 5, 4, 3, 5 4.1 ± 0.6 35.9
Naloxone vaccine 5, 5, 5, 4, 4, 6, 7 5.1 ± 1 20.3
Alum–naloxone vaccine 2, 3, 3, 3, 1, 3, 2 2.4 ± 0.7 62.5
Fig. 5  Worm recovery results in different vaccinated groups com-
pared to control (significant level, ****P < 0.0001 for all com-
parisons, except compared to group AL-VAC with P = 0.001), 
***P = 0.06 (comparison with the groups of CONT and AL-VAC), 
P = 0.08 (comparison with the group of VAC), **P = 0.001 (compari-
son with the groups of CONT, and VAC), *P = 0.6 (comparison with 
the group of CONT). CONT control, VAC vaccine, AL alum, NLX 
naloxone
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juvenile, adult and metacercariae stages of F. hepatica, 
respectively) in mice infected with F. hepatica metacer-
cariae. Furthermore, the recombinant DNA vaccines of 
cathepsin B expressed in young F. hepatica were shown 
to induce parasite-specific immune responses by boost-
ing high avidity IgG1, IgG2a and IgE immunoglobu-
lins in BALB/c female mice [25]. Previous vaccination 
experiments against fasciolosis used different adjuvants 
along with various antigenic determinants. Sansri et al. 
[39] used a combination of cathepsin L1H peptide of F. 
gigantica along with Freund’s adjuvant. Using this vac-
cination approach represented 66.1% protection in adju-
vant-vaccinated mice. This is similar to the protection 
rate that we observed in mice that were immunized with 
alum–NLX adjuvant. In a recent study, Kueakhai et al. 
[32] used recombinant saposin-like protein-1 of F. gigan-
tica along with alum adjuvant rendering 73% protection 
against fasciola infection. However, despite using Freund’s 
adjuvant, the previously mentioned approach activated a 
Th2 immune response [39]. This phenomenon may pro-
pose a role for antigenic components in influencing the 
nature of immune responses. In other studies, vaccination 
of mice with F. hepatica-derived phosphoglycerate kinase 
(PGK) peptide resulted in no elevation in Th1 response 
against the parasite [23, 45]. On the other hand, using non-
haemolytic Quillaja saponaria (QS) saponin as an adju-
vant along with F. hepatica recombinant fatty acid-binding 
protein (FABP) inhibited production of Th2 regulatory 
cytokines, and promoted the production of proinflam-
matory cytokines (IL-1 and IL-6) and IgG2a [43, 44]. In 
the present study, combination of E/S antigens seemed to 
accommodate the Th1 inductive properties of NLX. It is 
recommended, however, to incorporate various antigenic 
determinants with NLX adjuvant to establish this finding.
Mentioning limitations, we did not determine the IgE 
levels in immunized mice in our study. However, in the 
study of Jayaraj et al. [25], it was shown than IgE levels 
well-correlated with IgG1 and IgG2a immunoglobulins 
in BALB/c mice vaccinated with F. hepatica DNA vac-
cines. Furthermore, liver pathohistological changes and 
fluke sizes and biomass were not recorded in this study.
Conclusively, NLX, an opioid receptor antagonist, 
was revealed as a potential adjuvant to be utilized in E/S 
vaccines against fasciolosis. Both NLX and alum–NLX 
adjuvants promoted lymphocytic proliferation and Th1 
immune response. However, a combined alum–NLX 
adjuvant delivered a more potent Th1 immune response 
and higher protection rate. Considering that NLX is an 
opioid antagonist, it is recommended to further divulge 
the molecular determinants involved in opioid-derived 
signaling. A full knowledge of these pathways will assist 
us to develop new adjuvants addressing opioid-derived 
immunomodulatory mechanisms. As the safety profile of 
NLX has been excellent, it is recommended to consider 
this agent to be used in human and livestock vaccination 
against intracellular agents such as F. hepatica.
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